Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fourth Act For AbbVie's Risankizumab Whets Appetite

Executive Summary

AbbVie has released more positive top-line data for its anti-IL23 product risankizumab, building a strong case for its use in psoriasis – but there is still more to come from the study amid uncertainty over how the product will deal with competitive and pricing pressure.

You may also be interested in...



AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval

Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.

AbbVie's Skyrizi Poised To Enter Packed Psoriasis Market

AbbVie could be looking at near-simultaneous launches for Skyrizi on both sides of the Atlantic after the psoriasis drug – a key future growth driver – got a positive opinion from Europe's regulators some two months before the FDA is due to give its verdict on the interleukin-23 inhibitor.

Almirall To Put More Skin In The Game With Derma Buys

The Spanish company has a lot riding on tildrakizumab, the psoriasis drug licensed from Sun Pharma which could get the green light in Europe before year-end. Until then, Almirall is scouring the market for bolt-on deals.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel